Diabetes therapy to improve body mass index pulmoanry function in cystic fibrosis subjects with abnormal blood glucose

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-005019-28-GB

Enrollment

Registered

2005-04-19

Start date

2005-05-09

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis related diabetes mellitus

Interventions

Trade Name: NovoRapid Aspartate Pharmaceutical Form: Injection* INN or Proposed INN: Novo Rapid CAS Number: 133107-64-9 Current Sponsor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aged 18-65 Cystic fibrosis Normal fasting glucose (200mg/dl and patients whose two hour OGTT glucose is >140-200mg/dl and also have a glucose level during OGTT >200mg/dl within the last 12 months. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Acute illness within the last 12 months Current treatment with glucocorticoids Fasting hyperglycaemia >126mg/dl on more than two ocassions in past 12 months

Design outcomes

Primary

Measure	Time frame
Main Objective: To establish if an anti glycaemic induced increase in body mass index improves the pulmonary function of cystic fibrosis patients;Secondary Objective: Nil;Primary end point(s): FEV1	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026